 This is a phase 1 clinical trial to find the safe, maximum tolerated dose of IPI-504 in patients with relapsed andor relapsed, refractory multiple myeloma. This study will examine how IPI-504 is absorbed, distributed, metabolized, and eliminated by the body. The study will also evaluate potential anti-tumor activity of IPI-504. 